Interest of a Weekly Consultation by a Medical Electro Radiology Manipulator (MERM) in Addition to the Follow-up by the Radiotherapist to Improve the Collection of Radio-induced Toxicities in Patients Undergoing Proton Therapy

Interest of a Weekly Consultation by a Medical Electro Radiology Manipulator (MERM) in Addition to the Follow-up by the Radiotherapist to Improve the Collection of Radio-induced Toxicities in Patients Undergoing Proton Therapy: Randomized Controlled Trial

Status

Active, not recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05404308

Acronym

MERMOSE

Enrollment

Registered

2022-06-03

Start date

2023-05-17

Completion date

2026-07-31

Last updated

2025-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Tumor, Paramedical Consultation, Proton Therapy, Radiotherapy

Brief summary

To our knowledge, the investigators have not found any scientific article dealing with cooperation between radiation oncologists and medical radiation technologists in the context of monitoring patients undergoing radiotherapy. Cooperation protocols between health professionals are in progress but concern mainly technical procedures (ultrasound, laserthermal sessions). This study aims to evaluate whether MERMs, after training by physicians, can monitor clinical signs (for usual well-described toxicities) during treatment via a dedicated consultation. This approach participates in the development of new professions and cooperation protocols between health professionals. This mission of accompaniment on a dedicated time would make it possible to develop the caring role of the medical electroradiology manipulator.

Interventions

OTHERConsultation with Manipulator in Medical Radiology and a radiotherapist

Weekly consultation with Manipulator in Medical Radiology and a radiotherapist

OTHERConsultation with a radiotherapist

Weekly consultation with a radiotherapist

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

NONE

Intervention model description

Prospective randomized trial

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patient \> 18 years; * Patient with malignant or benign brain or upper aerodigestive tract (ADT) tumor candidate for proton therapy; * WHO score \< 2 * Mastery of the French language; * Patient affiliated with a social security system; * Signature of informed consent prior to any specific procedure related to the study.

Exclusion criteria

* Patient with another cancer previously treated with radiation therapy; * Simultaneous participation in a therapeutic clinical trial; * Patient deprived of liberty or under guardianship; * Any associated medical or psychological condition that may compromise the patient's ability to participate in the study * Patient unable to undergo trial monitoring for geographical, social or psychopathological reasons.

Design outcomes

Primary

Measure	Time frame
Proportion of patients with at least one toxicity requiring intervention	3 weeks

Secondary

Measure	Time frame
Number of toxicities detected	3 weeks

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026